Trial Profile
Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Mitomycin (Primary) ; Panitumumab (Primary)
- Indications Anal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms VITAL
- 05 Jun 2018 Primary endpoint (Three-year disease-free survival rate) has not been met, according to results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results (n=58) assessing efficacy and safety of the addition of panitumumab (Pmab) to fluorouracil (5-FU), mitomycin C (M) and radiotherapy (RT) standard treatment in patients with SCCAC, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 26 Mar 2017 Status changed from active, no longer recruiting to completed.